Giant Cell Arteritis

  • Richard A. Watts
  • David G. I. Scott
  • Chetan Mukhtyar


Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly. It is characterized by the involvement of the large vessels, predominantly the extracranial branches of the aorta. There is a close relationship with polymyalgia rheumatica (PMR). The first description of GCA was provided by Sir Jonathon Hutchinson in 1890, who described a patient at the London Hospital who could not wear a hat because of painful red streaks on his head. The painful streaks were thickened temporal arteries with feeble pulsations. The full description of the condition was provided by Bayard Horton in 1932.


Giant Cell Arteritis Temporal Artery Takayasu Arteritis Polymyalgia Rheumatica Retinal Artery Occlusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

Video 5.1

(AVI 15270 kb)


  1. 1.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001. Ann Rheum Dis. 2006;65(8):1093–8.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995;123(3):192–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55(1):131–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford). 2008;47(1):96–101.CrossRefGoogle Scholar
  7. 7.
    Parikh M, Miller NR, Lee AG, Savino PJ, Vacarezza MN, Cornblath W, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006;113(10):1842–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):​1594–7.CrossRefGoogle Scholar
  9. 9.
    Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318–23.CrossRefPubMedGoogle Scholar
  10. 10.
    Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49(5):703–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789–97.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, Cham 2015

Authors and Affiliations

  • Richard A. Watts
    • 1
  • David G. I. Scott
    • 2
  • Chetan Mukhtyar
    • 2
  1. 1.Department of RheumatologyIpswich Hospital NHS TrustIpswichUK
  2. 2.Department of RheumatologyNorfolk and Norwich University HospitalNorwichUK

Personalised recommendations